RLM.L Regulatory News (RLM)

PuriCore plc

("PuriCore" or the "Company")

11 October 2013

PuriCore Terminates Distribution Agreement

Company to pursue new partners for ultrasonic Wound Care application

PuriCore (LSE: PURI), a global company focused on safely and effectively protecting people from the spread of infectious pathogens, today announces it has reached an agreement with Misonix, Inc., to terminate the distribution agreement for a private-label version of PuriCore's Wound Care solution for use principally in conjunction with the Misonix line of ultrasonic systems. The parties had different views as to the interpretation of the distribution agreement, which was entered in July 2011, and the Directors determined that this settlement was the prudent course rather than to initiate potentially costly and distracting litigation. As such, the agreement has been terminated without any financial obligations by either party. The distribution agreement had been expected to deliver a total of approximately $1 million in gross margin to PuriCore over the course of 2013 and 2014.

PuriCore will expand the ultrasonic application of its Wound Care products with a new partner in this specialty field. The Company is currently in discussions with global marketing partners for new geographies and therapeutic markets. These new partnerships will supplement PuriCore's existing marketing partnerships with SteadMed Medical for Wound Care in North America and with Onset Dermatologics for Dermatology in the US. The Directors are confident that these business development initiatives along with other commercial activities will offset the margin loss.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safely and effectively protecting people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, PuriCore's portfolio provides savings to supermarket retailers in labour costs and improvements in inventory loss as well as addresses the issue of cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing in its research and development programmes in the UK on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.